Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma

(2018) Eileen M. O'Reilly et al.   CANCER

Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer

(2018) Erica S. Tsang et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma

(2017) Marine Gilabert et al.   MEDICINE

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma

(2017) Matthieu Sarabi et al.   Oncology Letters

A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer

(2017) Kensaku Yoshida et al.   Oncotarget

Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer

(2016) Hideki Ueno et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

(2015) Alix Portal et al.   BRITISH JOURNAL OF CANCER

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Identification of germline genetic mutations in patients with pancreatic cancer

(2015) Erin E. Salo-Mullen et al.   CANCER

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials

(2013) O. E. Rahma et al.   ANNALS OF ONCOLOGY

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE